AVEO Oncology announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. and its affiliates, to be added to the current tranched, $35 million debt facility secured with Hercules in August 2020 through an amendment to the amended and restated loan and security agreement (the “Loan Agreement”). Terms of the facility would remain otherwise unchanged from the Loan Agreement, with the loan bearing a maturity of 36 months, extendable up to 48 months, and an interest-only period of 12 months, extendable up to 30 months upon the achievement of performance milestones related to the approval and commercialization of tivozanib. Under the terms of the Loan Agreement, an initial tranche of $15 million was drawn down at signing. Under the terms of the commitment letter, a second tranche of $20 million would be available contingent upon the approval of the tivozanib New Drug Application (“NDA”) by the U.S. Food and Drug Administration (“FDA”) as a treatment for relapsed or refractory renal cell carcinoma (“RCC”). An additional $10 million will become available if certain sales criteria are met.